Vyome Holdings (HIND) Stock Overview
A clinical-stage specialty pharmaceutical company, develops therapeutic products targeting immuno-inflammatory and rare diseases in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
HIND Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Vyome Holdings, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.06 |
| 52 Week High | US$9.56 |
| 52 Week Low | US$1.75 |
| Beta | 0 |
| 1 Month Change | -7.21% |
| 3 Month Change | -10.43% |
| 1 Year Change | -71.78% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -85.29% |
Recent News & Updates
HIND: New Finance Leadership Will Support Future Earnings Multiple Expansion
Analysts have adjusted their price target on Vyome Holdings to $8.83 from $11.50, reflecting updated assumptions for revenue growth, profit margins and future P/E expectations. What’s in the News for Vyome Holdings Vyome Holdings appointed Jerry Leonard as Chief Financial Officer, effective September 1, 2026, following board approval on August 27, 2026.Rare Disease And Immuno Inflammatory Pipeline Will Drive Long Term Upside Potential
Catalysts About Vyome Holdings Vyome Holdings focuses on immuno-inflammatory and rare disease therapeutics with lead asset VT-1953 for malignant fungating wounds. What are the underlying business or industry changes driving this perspective?Recent updates
HIND: New Finance Leadership Will Support Future Earnings Multiple Expansion
Analysts have adjusted their price target on Vyome Holdings to $8.83 from $11.50, reflecting updated assumptions for revenue growth, profit margins and future P/E expectations. What’s in the News for Vyome Holdings Vyome Holdings appointed Jerry Leonard as Chief Financial Officer, effective September 1, 2026, following board approval on August 27, 2026.Rare Disease And Immuno Inflammatory Pipeline Will Drive Long Term Upside Potential
Catalysts About Vyome Holdings Vyome Holdings focuses on immuno-inflammatory and rare disease therapeutics with lead asset VT-1953 for malignant fungating wounds. What are the underlying business or industry changes driving this perspective?Shareholder Returns
| HIND | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -7.2% | -4.0% | -2.2% |
| 1Y | -71.8% | 43.7% | 13.1% |
Return vs Industry: HIND underperformed the US Pharmaceuticals industry which returned 43.7% over the past year.
Return vs Market: HIND underperformed the US Market which returned 13.1% over the past year.
Price Volatility
| HIND volatility | |
|---|---|
| HIND Average Weekly Movement | 5.3% |
| Pharmaceuticals Industry Average Movement | 8.8% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in US Market | 15.4% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: HIND has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: HIND's weekly volatility has decreased from 11% to 5% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 14 | N. Venkat Nelabhotla | www.vyometx.com |
Vyome Holdings, Inc., a clinical-stage specialty pharmaceutical company, develops therapeutic products targeting immuno-inflammatory and rare diseases in the United States. It operates through Pharmaceutical and Biotechnology segments. The company’s lead product candidate VT-1953, a dual DNA Gyrase/Topoisomerase inhibitor and immunomodulator in a topical gel formulation that is in phase 2 clinical stage for the treatment of bacterial conjunctivitis.
Vyome Holdings, Inc. Fundamentals Summary
| HIND fundamental statistics | |
|---|---|
| Market cap | US$14.74m |
| Earnings (TTM) | -US$11.31m |
| Revenue (TTM) | US$129.73k |
Is HIND overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| HIND income statement (TTM) | |
|---|---|
| Revenue | US$129.73k |
| Cost of Revenue | US$61.31k |
| Gross Profit | US$68.42k |
| Other Expenses | US$11.38m |
| Earnings | -US$11.31m |
Last Reported Earnings
Jun 30, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.61 |
| Gross Margin | 52.74% |
| Net Profit Margin | -8,716.70% |
| Debt/Equity Ratio | 0% |
How did HIND perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/09/11 01:18 |
| End of Day Share Price | 2026/09/11 00:00 |
| Earnings | 2026/06/30 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Vyome Holdings, Inc. is covered by 3 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Keay Nakae | Chardan Capital Markets, LLC |
| Theodore O'Neill | Litchfield Hills Research, LLC |
| Jason McCarthy | Maxim Group |